In-depth guide

UPDATED FEB 2026

Part of the Testosterone Therapy investigation

The short answer

The primary defendants in MDL 2545 are AbbVie (AndroGel), Eli Lilly (Axiron), Actavis/Allergan/Teva (Androderm), Pfizer (Depo-Testosterone), and Endo Pharmaceuticals (Testim, Fortesta — now in Chapter 11 bankruptcy). AbbVie's MDL docket is largely resolved via confidential settlement.

Eli Lilly and Actavis/Teva remain in active litigation. Endo plaintiffs must file through bankruptcy trust.

People's Justice Research TeamUpdated February 23, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

The testosterone therapy lawsuit names multiple defendants, each associated with specific TRT products. Identifying the correct defendant is important because settlement status, litigation posture, and available compensation pathways differ by manufacturer. AbbVie (AndroGel) has largely settled its MDL inventory. Eli Lilly (Axiron) and Actavis/Teva (Androderm) remain in active settlement discussions. Endo (Testim, Fortesta) requires a bankruptcy trust claim.

Pfizer's Depo-Testosterone — an injectable form — is the oldest TRT product and still widely prescribed. Pfizer's litigation exposure in MDL 2545 is smaller than AbbVie's given Depo-Testosterone's market share, but cases involving injectable testosterone are still being filed and evaluated. If you used any prescription testosterone product and suffered a cardiovascular injury, an attorney can identify the correct defendant and filing pathway for your specific situation.

The full investigation

Part of the Testosterone Therapy Investigation